New financial guidance for 2023:
Revenio Group’s exchange rate-adjusted net sales growth is estimated to be between 1 - 5 percent compared to the previous year and profitability, excluding non-recurring items, is estimated to remain at a good level.
Previous financial guidance for 2023, published on February 9, 2023:
Revenio Group’s exchange rate-adjusted net sales are estimated to grow strongly from the previous year and profitability, excluding non-recurring items, is estimated to remain at a good level.
President & CEO Jouni Toijala comments:
“Our operating environment is challenging. It is likely that the global challenges in our industry will continue. There are still uncertainties in the horizon related to the development of macroeconomics, such as inflation and high-interest rates, which we anticipate will affect the purchasing behavior of our customers in our main markets. We have already seen signs of caution in investment among opticians. We anticipate this to impact the demand for our products in the latter part of the year and, consequently, our net sales development during the latter part of 2023. For the same reasons, we also anticipate a general market slowdown, and we currently see no clear indications of market conditions improving in the second half of the year.”
Revenio Group Corporation’s half-year financial report for January-June 2023 will be published on August 10, 2023.
Revenio Group Corporation
Board of Directors
For further information, please contact
Jouni Toijala, President & CEO, tel. +358 50 484 0085
jouni.toijala@revenio.fi
Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
Distribution
Nasdaq Helsinki Oy
Principal media
Financial Supervisory Authority (FIN-FSA)
www.reveniogroup.fi/en/
Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
In 2022, the Group’s net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.